Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
Public ClinicalTrials.gov record NCT00195260. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Dose-Escalation Study Of Oral SKI-606 In Subjects With Advanced Malignant Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety and tolerability of oral SKI-606 (bosutinib) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (MTD) in this subject population.
Study identification
- NCT ID
- NCT00195260
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 151 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2004
- Primary completion
- Oct 31, 2007
- Completion
- Oct 31, 2007
- Last update posted
- Feb 10, 2013
2004 – 2007
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmington | Alabama | 35233 | — |
| Pfizer Investigational Site | Scottsdale | Arizona | 85258 | — |
| Pfizer Investigational Site | Los Angeles | California | 90033 | — |
| Pfizer Investigational Site | Tampa | Florida | 33612 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30341 | — |
| Pfizer Investigational Site | Indianpolis | Indiana | 46202 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21287 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48202 | — |
| Pfizer Investigational Site | Lansing | Michigan | 48910 | — |
| Pfizer Investigational Site | New York | New York | 10016 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28203 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28211 | — |
| Pfizer Investigational Site | UNC Chapel Hill | North Carolina | 27514 | — |
| Pfizer Investigational Site | UNC Chapel Hill | North Carolina | 27759 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44106-1736 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78258 | — |
| Pfizer Investigational Site | Tyler | Texas | 75702 | — |
| Pfizer Investigational Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00195260, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2013 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00195260 live on ClinicalTrials.gov.